MedTrace Logo

Tocilizumab for the Treatment of Familial Mediterranean Fever

NCT03446209 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-18

No results posted yet for this study

Summary

Adult patients with Familial Mediterranean Fever, who have active disease

Conditions

  • Familial Mediterranean Fever

Interventions

DRUG

Tocilizumab Infusion RoAcemtra (EU)

Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks

DRUG

0.9% physiological saline

Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get "rescue medication" after week 16 to week 28.

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-23
Primary Completion
2020-10-30
Completion
2020-10-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03446209 on ClinicalTrials.gov